|
Management
 Dr. George Adams
Chief Executive Officer and Director
Dr. Adams is a scientist and serial entrepreneur providing
leadership, senior management and strategic guidance to life sciences companies
in roles including CEO or board participation. Dr. Adams was the President and
CEO of the Innovations Foundation from 1999 until 2004, where he was involved
in creating companies and commercializing technologies. Prior to this, he held
research and executive positions with Boston Scientific Inc, Pfizer Inc.,
Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood
Transfusion Service. He has also
been a founding angel investor in six start-up companies in Canada and the
United States. He has been instrumental
in obtaining venture financing for 24 companies who have raised $85 million and
has been a Director of 10 venture capital funds and 8 start-up companies. Dr.
Adams has 124 publications including 9 invited reviews, 26 full papers and 3
patents. He is a past President of the Canadian Biomaterials Society. He has
been a reviewer for numerous scientific journals, national granting agencies
and several national and provincial centres of excellence. He has been a
principal investigator for over $40 million in private and publicly-funded
research and development. Dr. Adams is a graduate of the Rotman School of Management Director's Education Program.
 Dr. Neil Cashman
Chief Scientific Officer and Co-founder
Dr. Cashman is a physician and scientist focused on
neurodegenerative diseases. From 1998 to 2005, Dr. Cashman served as Professor
at the University of Toronto. He has served as the Diener (endowed) Chair of
Neurodegenerative Diseases. He is a Principal Investigator at the Center of
Research in Neurodegenerative Diseases, and has served as Director of the
Neuromuscular Clinic at Sunnybrook and Women's Hospital. Beginning in 2005, Dr.
Cashman will serve as Professor at the University of British Columbia and has
been named as the Canada Research Chair in Neurodegeneration and Protein
Misfolding Diseases. In addition, he has been named the Director of the ALS
Clinic at the Vancouver General Hospital in British Columbia. He has procured
nearly $12 million in research grant funding from the CIHR, CRC, NIH and
various corporations for his work involving protein misfolding and prion technology.
In 2000, he was awarded the Jonas Salk Prize for biomedical research. He is
recognized worldwide as one of the principal leading research scientists and
experts pioneering the emerging fields of protein misfolding as well as prion
diagnostic and therapeutic development.
 James Parsons
Chief Financial Officer
Mr. Parsons is a Chartered Accountant with an extensive
background in life sciences industry. From 2003 until present he has provided
CFO and consulting services to both public and private life sciences companies.
From 2000 to 2003 he was Vice President Finance and Administration at Lorus
Therapeutics Inc. a TSX listed company. From 1995 until 2000 Mr. Parsons held
various financial positions with Timminco Limited, a specialty metals
manufacturer and was Controller and Assistant Treasurer at the time of his
departure. Mr. Parsons worked at CAE Inc. from 1991 to 1995 and prior thereto
he was with the accounting firm of KPMG. Mr. Parsons holds a Bachelor of Arts
with Honours and a Master of Accounting from the University of Waterloo and is
also a Certified Management Accountant.
 Vigen Nazarian
Vice President, Strategic Alliances and Co-founder
Mr. Nazarian previously served as Technology and Business
Development Manager, Life Sciences, for the Innovations Foundation of the
University of Toronto since 2000. For the past ten years he has successfully licensed life
science, agricultural biotechnology, medical device diagnostic and
pharmaceutical technologies arising from academic institutions as well as established five technology based start-ups within the university enironment. From 1989 to 2000, he
served as Senior Research Associate for Pioneer Hi-Bred International, the
leading developer and supplier of advanced plant genetics material. Through his consulting firm, Naprico Inc., Mr Nazarian has been providing strategic advice and management direction to early-stage science-based companies.
|
